Does the "switch the plane" strategy improve outcomes? Anterior vs. posterior repair for recurrence after prior inguinal hernia repair: a systematic review and meta-analysis.

HerniaOct 26, 2026 (epub)
Clinical ResearchGeneral SurgeryOpen access

Gabriela Lyons, Vitor Neves, Letícia Hanna Moura da Silva Gattas Graciolli et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined outcomes of recurrent unilateral inguinal hernia repair by operative plane, including comparative studies of posterior versus repeat anterior repair after prior anterior repair. Across 35 studies involving 4,902 patients, pooled comparative data showed no statistically significant difference in recurrence (OR 0.70, 95% CI 0.39-1.27). Posterior repair was associated with lower odds of surgical site infection (OR 0.24, 95% CI 0.07-0.79); chronic pain and seroma did not differ significantly in the primary analyses. The evidence therefore offers limited support for superiority of the “switch the plane” strategy on recurrence.

Key findings

  • Recurrence did not differ significantly between posterior and repeat anterior repair after prior anterior repair (OR 0.70, 95% CI 0.39-1.27).
  • Posterior repair was associated with lower odds of surgical site infection than repeat anterior repair (OR 0.24, 95% CI 0.07-0.79).
  • Chronic postoperative pain showed no significant difference in the primary analysis (OR 0.47, 95% CI 0.22-1.00), but was lower with posterior repair in the RCT-only sensitivity analysis (OR 0.36, 95% CI 0.16-0.81).
  • After posterior repair following prior anterior repair, pooled recurrence was 2% (95% CI 0.01-0.03) across 17 studies.

Why it matters

The review evaluates a widely used guideline-supported approach to recurrent hernia repair and finds that its presumed recurrence advantage is not demonstrated in the pooled comparative evidence. The lower odds of surgical site infection with posterior repair may inform discussion of operative approach, while the findings on pain and recurrence underscore that outcomes differ by endpoint and analysis.

What to keep in mind

Comparative evidence was limited: six studies compared approaches after prior anterior repair, and only one study assessed anterior repair after prior posterior repair, precluding quantitative synthesis. The abstract also reports substantial heterogeneity for some pooled outcomes.

Source

Published in Hernia. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in General Surgery

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.